Work

TG4010

Year: 2012

Type: article

Abstract: TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2. Today the clinical development is focused on advanced non-small cell lung cancer in combination with first line chemotherapy. Potential biomarkers predictive of activity have been identified.

Source: OncoImmunology

DOI: 10.4161/onci.19863

Authors: Jean-Marc Limacher, Elisabeth Quoix

Institutions: Transgene (France), Hôpitaux Universitaires de Strasbourg, Hôpital Civil, Strasbourg

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913